

MSF Scientific Days 18-20 May 2021

Agenda 2021



Health promoter uses a megaphone to inform people of the steps to follow during distribution, DRC

Agenda for Medical Research, Day 1

Day 1: Tuesday 18 May

* all times Coordinated Universal Time (UTC)

Conference Welcome: **Javid Abdelmoneim**, *President, MSF UK Board of Trustees*.

9:30 Introduction & Welcome by **Vickie Hawkins**, *Executive Director, MSF UK*.

Session 1, Day 1 - Different approaches to learning from communities

9:35 Session Chair: **Kamalini Lokuge**, *Lead, Humanitarian Health Research Initiative, Australian National University*.

1. High levels of mortality above the emergency threshold, Central African Republic: population-based mortality survey, 2020. **Eve Robinson**, *MSF, Bangui, Central African Republic*.
2. Knowledge, attitudes, practices and behaviour of maternity ward staff in relation to comprehensive abortion care in a conflict-affected setting, Bangui, Central African Republic: cross-sectional survey. **Huiwu Chen**, *Epicentre, Paris, France*.
3. Engaging men in preventing sexual violence in South Sudan and the Central African Republic: a qualitative study. **Emilie Venables**, *International Committee of the Red Cross (ICRC), Geneva, Switzerland*.

10:50 Break | Join the speakers for an informal Q&A in the networking lounge

Session 2, Day 1 - Community-centred programming - panel discussion

11:20 Session Chair: **Tom Ellman**, *Director Southern Africa Medical Unit, MSF*.

Panellists:

1. **Zipporah Ali**, *Executive Director, Kenya Hospices and Palliative Care Association*.
2. **Vidya Raghaven**, *Director of Communications, New Concept Information Systems*.
3. **Sohana Sadique**, *Epidemiologist and Study Coordinator, MSF Bangladesh*.
4. **Jerome Singh**, *Adjunct Professor in the division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Canada and Honorary Research Fellow at Howard College School of Law, University of KwaZulu-Natal, Durban, South Africa*.
5. **Animesh Sinha**, *HIV, TB & Hepatitis Advisor, MSF UK*.
6. **Marion Stevens**, *Founding Director, Sexual and Reproductive Justice Coalition, South Africa*.

12:20 Break

Session 3, Day 1 - Covid-19: Health, life and death in a pandemic

13:10 Session Chair: **Yap Boum**, *Epicentre Representative for Africa*.

1. Community perceptions of COVID-19 prevention and control measures in Nigeria and Sierra Leone: multisite, community-led qualitative study. **Emily Briskin**, *MSF, Amsterdam, The Netherlands & Aminu Mohammed Anka*, *MSF, Anka, Nigeria*.
2. Estimation of SARS-CoV-2 infections and deaths among Rohingya refugees, Kutupalong-Balukhali camps, Bangladesh. **Shaun Truelove**, *Johns Hopkins University, Baltimore, USA*.

14:25 Day 1 Closing Remarks by **Farhat Mantoo**, *General Director, MSF India*.

Agenda for Medical Research, Day 2

Day 2: Wednesday 19 May

* all times Coordinated Universal Time (UTC)

9:30 Introduction by **Petros Isaakidis**, *Senior Operational Research Advisor, Southern Africa Medical Unit, MSF.*

Session 1, Day 2 - Malnutrition: new norms, adapted protocols

9:35 Session Chair: **Alexandra Rutishauser-Perera**, *Head of Nutrition, Action Against Hunger UK.*

1. Optimising malnutrition treatment in children 6-59 months: primary outcome of a randomized trial, Democratic Republic of Congo. **Cecile Cazes**, *University of Bordeaux, Bordeaux, France.*
2. Optimal mid-upper arm circumference-based discharge criteria for community-based-management of severe acute malnutrition in India: a randomized controlled non-inferiority trial. **Elisa Marino**, *MSF, New Delhi, India.*
3. Evolution of nutritional status in children aged 6-59 months with moderate acute malnutrition in India: a prospective longitudinal cohort study. **Raman Mahajan**, *MSF, New Delhi, India.*

10:50 Break | Join the speakers for an informal Q&A in the networking lounge.

Session 2, Day 2 - Hidden patients and challenges in HIV and TB

11:20 Session Chair: **Nathan Ford**, *Scientist, Department of HIV, World Health Organisation.*

1. Prevalence of asymptomatic Leishmania infection in HIV-positive people and progression to symptomatic visceral leishmaniasis in Bihar, India. **Sakib Burza**, *MSF, New Delhi, India.*
2. Diagnostic performance of lateral flow point-of-care HIV-Combo testing for detection of acute HIV infection in Eswatini. **Bernhard Kerschberger**, *MSF, Mbabane, Eswatini.*
3. Challenging experiences of children, adolescents, and their caregivers during the treatment journey for drug-resistant tuberculosis: qualitative study, Mumbai, India. **Mrinalini Das**, *MSF, Mumbai, India.*
4. Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis. **Catherine Berry**, *MSF, London, UK.*

12:50 Break | Join the speakers for an informal Q&A in the networking lounge.

Session 3, Day 2 - Targeting malaria in fragile and conflict settings

13:20 Session Chair: **Valentina Buj**, *Global Malaria and Health Partnerships Advisor, UNICEF.*

1. Revision of the epidemiological situation of malaria in Burundi and the potential implications for future control. **Jean-Marie Mafuko**, *MSF, Brussels, Belgium.*
2. Mass drug administration of long-acting antimalarials among children in Bossangoa health district, Central African Republic: programme description and evaluation. **Eve Robinson**, *MSF, Bangui, Central African Republic.*
3. Feasibility of large-scale mass drug administration for malaria in Angumu health zone, Ituri, Democratic Republic of Congo. **Trish Newport**, *MSF, Geneva, Switzerland.*

14:35 Day 2 Closing Remarks by **Kiran Jobanputra**, *Head of the Manson Unit, MSF UK, and Deputy Medical Director, MSF Operational Centre Amsterdam.*

Agenda for Innovation, Day 3

Day 3: Thursday 20 May

* all times Coordinated Universal Time (UTC)

9:30 Introduction by **Tammam Aloudat**, *Senior Strategic Advisor, MSF Access Campaign.*

Session 1, Day 3 - Striving to develop sustainable and adaptable humanitarian structures

9:50 Session Chair: **Nan Buzard**, *Head of Innovation, International Committee of the Red Cross.*

1. The Environmental Impact Toolkit: futureproofing MSF through measurement and mitigation. **Sandra Smiley**, *MSF, Toronto, Canada.*
2. FriGo: an actively cooled, portable cold chain solution for resource limited settings. **Eric Saldanha**, *Royal College of Art, London, UK.*
3. Investing in people; higher education programmes in MSF. **Bart Janssens**, *MSF Academy for Healthcare*, **Caroline King**, *Leadership Education Academic Partnership (LEAP)*, **Parvati Nair**, *Global Health and Humanitarian Medicine (GHHM) course*, **Roger Teck**, *GHHM and LEAP.*

11:05 Break | Join the speakers for an informal Q&A in the networking lounge

Session 2, Day 3 - Bridging gaps to communities and patients

11:35 Session Chair: **Pete Masters**, *Head of Community, Humanitarian OpenStreetMap Team.*

1. Photovoice: addressing stigma among people living with drug-resistant tuberculosis in India. **Tanya Mathur**, *MSF, Mumbai, India.*
2. CommunityFirst Solutions: supporting community-driven responses to COVID-19. **Jessica Farber**, *SeeChange Initiative, Montreal, Canada.*
3. Overcoming lockdown restrictions by digitising health promotion. **Jakub Hein**, *MSF, Brussels, Belgium.*

12:50 Break | Join the speakers for an informal Q&A in the networking lounge.

Session 3, Day 3 - Digital Health: The opportunities and challenges in humanitarian settings

13:20 Session Chair: **Massimo Ravasini**, *Head of Innovation and Project Management, MSF Japan.*

1. Video/Virtually Observed Therapy for patients with drug-resistant tuberculosis in Eswatini: a rapid response to COVID-19 lockdown measures. **Michelle Daka**, *MSF, Nhlanguano, Eswatini.*
2. AntibioGo: smartphone-based application to tackle antibiotic resistance challenges in low-to-middle income countries. **Nada Malou**, *MSF Foundation, Paris, France.*
3. A digital portable tablet audiometry monitoring tool for patients with drug-resistant tuberculosis. **Nuria Veloso Cumbi**, *MSF, Maputo, Mozambique.*

14:35 Day 3 & Conference Closing Remarks by **Kiran Jobanputra**, *Head of the Manson Unit, MSF UK, and Deputy Medical Director, MSF Operational Centre Amsterdam.*